The case for early detection (original) (raw)

• National Cancer Institute. Surveillance Epidemiology and End Results Program [online], (cited 19 Nov 2002), http://seer.cancer.gov/ (2002).
• Winawer, S. J. et al. Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. Bull. World Health Organ. 73, 7–10 (1995).
  CAS PubMed PubMed Central Google Scholar
• Bell, R., Petticrew, M. & Sheldon, T. The performance of screening tests for ovarian cancer: results of a systematic review. Br. J. Obst. Gynaecol. 105, 1136–1147 (1998).
  Article CAS Google Scholar
• Henschke, C. Early Lung Cancer Action Project: overall design and findings from baseline screening. Cancer 89, 274–282 (2000).
  Article Google Scholar
• Henschke, C. et al. Early Lung Cancer Action Project: initial findings on repeat screening. Cancer 92, 153–159 (2001).
  Article CAS Google Scholar
• Mahadevia, P. J. et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 289, 313–322 (2003).
  Article Google Scholar
• Grann, V. R. & Neugut, A. I. Lung cancer screening at any price? JAMA 289, 357–358 (2003).
  Article Google Scholar
• Etzioni, R. et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J. Natl Cancer Inst. 94, 981–990 (2002).
  Article Google Scholar
• Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–577 (2002). This article illustrates the potential utility of serum proteomics in developing sensitive and specific cancer screening tests.
  Article CAS Google Scholar
• Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–826 (2001).
  Article CAS Google Scholar
• Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001). First paper to propose the classification of biomarker studies into five phases.
  Article CAS Google Scholar
• Pepe, M. S., Longton, G. M., Anderson, G. L. & Schummer, M. Selecting Differentially Expressed Genes from Microarray Experiments UW Biostatistics Working Paper Series. Working Paper 184 [online], (cited 24 Jan 2003), http://www.bepress.com/uwbiostat/paper184 (2003).
  Google Scholar
• Tusher, V. G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl Acad. Sci. USA 98, 5116–5121 (2001).
  Article CAS Google Scholar
• Yeung, K. Y., Haynor, D. R. & Ruzzo, W. L. Validating clustering for gene expression data. Bioinformatics 17, 309–318 (2001).
  Article CAS Google Scholar
• Yeung, K. Y., Fraley, C., Murua, A., Raftery, A. E. & Ruzzo, W. L. Model-based clustering and data transformations for gene expression data. Bioinformatics 17, 977–987 (2001).
  Article CAS Google Scholar
• Hastie, T., Tibshirani, R. & Friedman, J. The Elements of Statistical Learning: Data Mining, Inference and Prediction (Springer–Verlag, New York, 2001).
  Book Google Scholar
• Gann, P. H., Hennekens, C. H. & Stampfer, M. J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273, 289–294 (1995).
  Article CAS Google Scholar
• McIntosh, M., Urban, N. & Karlan, B. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol. Biomarkers Prev. 11, 159–166 (2002).
  PubMed Google Scholar
• Carter, H. B. & Pearson, J. D. Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol. Clin. N. Am. 24, 333–338 (1997).
  Article CAS Google Scholar
• Polascik, T. J., Oesterling, J. E. & Partin, A. W. Prostate specific antigen: a decade of discovery — what we have learned and where we are going. J. Urol. 162, 293–306 (1999).
  Article CAS Google Scholar
• Skates, C. J., Pauler, D. K. & Jacobs, I. Screening based on the risk of cancer calculation from Bayesian hierarchical change-point models of longitudinal markers. J. Am. Stat. Assoc. 96, 429–439 (2001).
  Article Google Scholar
• Carter, H. B. et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 52, 3323–3328 (1992).
  CAS PubMed Google Scholar
• Woods, W. G. et al. Screening of infants and mortality due to neuroblastoma. N. Engl. J. Med. 346, 1041–1046 (2002).
  Article Google Scholar
• Farrow, D. C. & Vaughan, T. L. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 7, 322–327 (1996).
  Article CAS Google Scholar
• Conio, M. et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 48, 304–309 (2001).
  Article CAS Google Scholar
• Drewitz, D. J., Sampliner, R. E. & Garewal, H. S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed for 8 years. Am. J. Gastroenterol. 92, 212–215 (1997).
  CAS PubMed Google Scholar
• Schnell, T. G. et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 120, 1607–1619 (2001).
  Article CAS Google Scholar
• Reid, B., Blount, P. & Rabinovitch, P. Biomarkers in Barrett's esophagus: a guideline for clinicians. Gastrointest. Clin. N. Am. (in the press).
• Alikhan, M. et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 50, 23–26 (1999).
  Article CAS Google Scholar
• Ofman, J. J. et al. The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am. J. Gastroenterol. 96, 876–881 (2001).
  Article CAS Google Scholar
• Macdonald, C. E., Wicks, A. C. & Playford, R. J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 321, 1252–1255 (2000).
  Article CAS Google Scholar
• Connor, R. J., Prorok, P. C. & Weed, D. L. The case-control design and the assessment of the efficacy of cancer screening. J. Clin. Epidemiol. 44, 1215–1221 (1991).
  Article CAS Google Scholar
• Cronin, K. A., Weed, D. L., Connor, R. J. & Prorok, P. C. Case-control studies of cancer screening: theory and practice. J. Natl Cancer Inst. 90, 498–504 (1998).
  Article CAS Google Scholar
• Weiss, N. S. Case-control studies of the efficacy of screening for cancer: can we earn them some respect. J. Med. Screen. 4, 57–59 (1997). References 32–34 discuss the use of case–control studies for evaluating cancer screening with special attention to avoiding bias.
  Article CAS Google Scholar
• Etzioni, R. et al. Cancer surveillance series: interpreting trends in prostate cancer. Part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J. Natl Cancer Inst. 91, 1033–1039 (1999).
  Article CAS Google Scholar
• Feuer, E. J., Mariotto, A. & Merrill, R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer 95, 870–880 (2002).
  Article Google Scholar
• Schatzkin, A. & Gail, M. The promise and peril of surrogate end points in cancer research. Nature Rev. Cancer 2, 19–27 (2002).
  Article CAS Google Scholar
• Hirsch, F. R. et al. IV international conference on prevention and early detection of lung cancer, Reykjavik, Iceland, August 9–12, 2001. Lung Cancer 37, 325–344 (2002).
  Article Google Scholar
• Friedman, D. R. & Dubin, N. Case-control evaluation of breast cancer screening efficacy. Am. J. Epidemiol. 133, 974–984 (1991).
  Article CAS Google Scholar
• Newcomb, P. A. et al. Breast self-examination in relation to the occurrence of advanced breast cancer. J. Natl Cancer Inst. 83, 260–265 (1991).
  Article CAS Google Scholar
• Hurley, S. F. & Kaldor, J. M. The benefits and risks of mammographic screening for breast cancer. Epidemiol. Rev. 14, 101–130 (1992).
  Article CAS Google Scholar
• Palli, D. et al. A case-control study of the efficacy of a non-randomized breast cancer screening program in Florence (Italy). Int. J. Cancer 38, 501–504 (1986).
  Article CAS Google Scholar
• Selby, J. V., Friedman, G. D., Quesenberry, C. P. Jr & Weiss, N. S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 326, 653–657 (1992).
  Article CAS Google Scholar
• Beemsterboer, P. M. et al. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J. Urol. 164, 1216–1220 (2000).
  Article CAS Google Scholar
• Gohagan, J. K., Prorok, P. C., Hayes, R. B. & Kramer, B. S. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin. Trials 21, 251S–272S (2000).
  Article CAS Google Scholar
• Bartsch, G. et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58, 417–424 (2001).
  Article CAS Google Scholar
• Lu–Yao, G. et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325, 740 (2002).
  Article Google Scholar
• Oliver, S. E., May, M. T. & Gunnell, D. International trends in prostate-cancer mortality in the 'PSA ERA'. Int. J. Cancer 92, 893–898 (2001). References 46–48 are examples of recent population studies of PSA screening.
  Article CAS Google Scholar
• Harris, R. & Lohr, K. N. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 137, 917–929 (2002).
  Article Google Scholar
• Brown, M. L. & Fintor, L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res. Treat. 25, 113–118 (1993). Explores the reasons for variability in estimates of the cost-effectiveness of screening interventions.
  Article CAS Google Scholar
• Rosenquist, C. J. & Lindfors, K. K. Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer 82, 2235–2240 (1998).
  Article CAS Google Scholar
• Salzmann, P., Kerlikowske, K. & Phillips, K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann. Intern. Med. 127, 955–965 (1997). References 51 and 52 show how different results of cost-effectiveness studies of the same intervention can be.
  Article CAS Google Scholar
• Pignone, M., Saha, S., Hoerger, T. & Mandelblatt, J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann. Intern. Med. 137, 96–104 (2002).
  Article Google Scholar
• van der Maas, P. J. et al. The cost-effectiveness of breast cancer screening. Int. J. Cancer 43, 1055–1060 (1989).
  Article CAS Google Scholar
• US Congress Office of Technology Assessment. Costs and Effectiveness of Prostate Cancer Screening in Elderly Men (US Government Printing Office, Washington DC, 1995).
• Etzioni, R., Cha, R. & Cowen, M. E. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J. Urol. 162, 741–748 (1999).
  Article CAS Google Scholar
• Ross, K. S., Carter, H. B., Pearson, J. D. & Guess, H. A. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284, 1399–1405 (2000).
  Article CAS Google Scholar
• Boyes, D. A. The value of a pap smear program and suggestions for its implementation. Cancer 48, 613–621 (1981).
  Article CAS Google Scholar
• Christopherson, W. M., Parker, J. E. & Mendez, W. M. Cervix cancer death rates and mass cytologic screening. Cancer 26, 808–811 (1970).
  Article CAS Google Scholar
• Schiffman, M. H., Brinton, L. A., Devesa, S. S. & Fraumeni, J. F. Jr in Cancer Epidemiology and Prevention 2nd edn (eds Schottenfeld, D. & Fraumeni, J. F. Jr) 1090–1116 (Oxford Univ. Press, New York, 1996).
  Google Scholar
• Parkin, D. M., Pisani, P. & Ferlay, J. Estimates of the worldwide frequency of eighteen major cancers in 1985. Int. J. Cancer 54, 594–606 (1993).
  Article CAS Google Scholar
• Cuzick, J. Time to consider HPV testing in cervical screening. Ann. Oncol. 12, 1511–1514 (2001).
  Article CAS Google Scholar
• Stoler, M. H. HPV for cervical cancer screening: is the era of the molecular pap smear upon us? J. Histochem. Cytochem. 49, 1197–1198 (2001).
  Article CAS Google Scholar
• Cuzick, J. et al. Human papillomavirus testing in primary cervical screening. Lancet 345, 1533–1536 (1995).
  Article CAS Google Scholar
• Kulasingam, S. L. et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288, 1749–1757 (2002).
  Article Google Scholar
• Ratnam, S., Franco, E. L. & Ferenczy, A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol. Biomarkers Prev. 9, 945–951 (2000).
  CAS PubMed Google Scholar
• Woolas, R. P. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol. 59, 111–116 (1995).
  Article CAS Google Scholar
• Woolas, R. P. et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl Cancer Instit. 85, 1748–1751 (1993).
  Article CAS Google Scholar
• Bates, J. et al. Clinical value of CYFRA 21.1, carcinoembryonic antigen, neurone-specific enolase, tissue polypeptide specific antigen and tissue polypeptide antigen in the diagnosis of lung cancer. Eur. Resp. J. 10, 2535–2538 (1997).
  Article CAS Google Scholar
• Beduschi, M. C. & Oesterling, J. E. Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing. Urology 51, 98–109 (1998).
  Article CAS Google Scholar
• Brawer, M. K. Prostate-specific antigen: current status. CA Cancer J. Clin. 49, 264–281 (1999).
  Article CAS Google Scholar
• Catalona, W. J. et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279, 1542–1547 (1998).
  Article CAS Google Scholar
• Gann, P. H., Ma, J., Catalona, W. J. & Stampfer, M. J. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J. Urol. 167, 2427–2434 (2002).
  Article Google Scholar
• Zhang, Z. et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73, 56–61 (1999).
  Article CAS Google Scholar
• McIntosh, M. W. & Pepe, M. Combining several screening tests: optimality of the risk score. Biometrics 58, 657–664 (2002).
  Article Google Scholar
• Baker, S. G. Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics 56, 1082–1087 (2000).
  Article CAS Google Scholar
• Etzioni, R., Kooperberg, C., Pepe, M. S., Smith, R. & Gann, P. H. Combining biomarkers to detect disease with application to prostate cancer. Biostatistics (in the press). References 74–77 present new statistical methods for identifying optimal combinations of biomarkers.
• Optenberg, S. A. et al. Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test. Urology 50, 665–672 (1997).
  Article CAS Google Scholar
• Urban, N., Drescher, C., Clarke, L. & Kiviat, N. in Ovarian Cancer 5 (eds Sharp, F., Blackett, T., Berek, J. & Bast, R.) 217–229 (Isis Medical Media Ltd., Oxford, 1998).
  Google Scholar
• Urban, N. et al. in Ovarian Cancer (ed. Jacobs, I.) 199–208 (Oxford Univ. Press, 2002).
  Google Scholar
• Urban, N. Screening for ovarian cancer. BMJ 319, 1317–1318 (1999).
  Article CAS Google Scholar
• American Cancer Society. Costs of Cancer, 2002 [online], (cited 25 Jan 2003), http://www.cancer.org/docroot/MIT/content/MIT\_3\_2X\_Costs\_of\_Cancer.asp (2002).
• Gold, M. E., Siegel, J. E., Russell, L. B. & Weintstein, M. C. Cost–Effectiveness in Health and Medicine (Oxford Univ. Press, New York, 1996).
  Google Scholar
• US Congress Office of Technology Assessment. Breast Cancer Screening for Medicare Beneficiaries; Effectiveness, Costs to Medicare and Medical Resources Required (US Government Prinitng Office, Washington DC, 1987).
• Shibata, A. & Whittemore, A. S. Re: Prostate cancer incidence and mortality in the United States and the United Kingdom. J. Natl Cancer Inst. 93, 1109–1110 (2001).
  Article CAS Google Scholar
• Crocetti, E., Ciatto, S. & Zappa, M. Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy. J. Natl Cancer Inst. 93, 876–877 (2001).
  Article CAS Google Scholar